Measurable residual disease testing for personalized treatment of acute myeloid leukemia
(2019) In APMIS 127(5). p.337-351- Abstract
This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5f0bb456-67b6-4f17-9add-f48d4d6b1831
- author
- Ehinger, Mats LU and Pettersson, Louise LU
- organization
- publishing date
- 2019-03-28
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Acute myeloid leukemia, CBF leukemia, CBFB-MYH11, flow cytometry, inv(16), measurable residual disease, multicolor flow cytometry, NPM1, personalized treatment, RUNX1-RUNX1T1, t(16;16), t(8;21)
- in
- APMIS
- volume
- 127
- issue
- 5
- pages
- 337 - 351
- publisher
- John Wiley & Sons Inc.
- external identifiers
-
- pmid:30919505
- scopus:85063576379
- ISSN
- 0903-4641
- DOI
- 10.1111/apm.12926
- language
- English
- LU publication?
- yes
- id
- 5f0bb456-67b6-4f17-9add-f48d4d6b1831
- date added to LUP
- 2019-04-08 13:17:20
- date last changed
- 2024-09-03 16:00:29
@article{5f0bb456-67b6-4f17-9add-f48d4d6b1831, abstract = {{<p>This review summarizes – with the practicing hematologist in mind – the methods used to determine measurable residual disease (MRD) in everyday practice with some future perspectives, and the current knowledge about the prognostic impact of MRD on outcome in acute myeloid leukemia (AML), excluding acute promyelocytic leukemia. Possible implications for choice of MRD method, timing of MRD monitoring, and guidance of therapy are discussed in general and in some detail for certain types of leukemia with specific molecular markers to monitor, including core binding factor (CBF)-leukemias and NPM1-mutated leukemias.</p>}}, author = {{Ehinger, Mats and Pettersson, Louise}}, issn = {{0903-4641}}, keywords = {{Acute myeloid leukemia; CBF leukemia; CBFB-MYH11; flow cytometry; inv(16); measurable residual disease; multicolor flow cytometry; NPM1; personalized treatment; RUNX1-RUNX1T1; t(16;16); t(8;21)}}, language = {{eng}}, month = {{03}}, number = {{5}}, pages = {{337--351}}, publisher = {{John Wiley & Sons Inc.}}, series = {{APMIS}}, title = {{Measurable residual disease testing for personalized treatment of acute myeloid leukemia}}, url = {{http://dx.doi.org/10.1111/apm.12926}}, doi = {{10.1111/apm.12926}}, volume = {{127}}, year = {{2019}}, }